Everolimus/Sorafenib or Sunitinib in Patients With Metastatic Renal Cell Carcinoma (RCC)
Status:
Withdrawn
Trial end date:
2016-04-01
Target enrollment:
Participant gender:
Summary
This is a phase II trial that follows the completion of the phase I UCSF trial of everolimus
and sorafenib for Renal Cell Carcinoma (RCC). This trial will be for patients who have not
had treatment for RCC before. This trial will have 2/3 patients getting everolimus/sorafenib
treatment and 1/3 getting sunitinib, an FDA approved RCC drug. All three drugs are approved
for advanced RCC when used individually, the combination of everolimus and sorafenib for RCC
is not approved by the FDA.